Literature DB >> 35074509

The development and progress of nanomedicine for esophageal cancer diagnosis and treatment.

Xiaokun Li1, Lingmin Chen2, Siyuan Luan1, Jianfeng Zhou1, Xin Xiao1, Yushang Yang1, Chengyi Mao1, Pinhao Fang1, Longqi Chen1, Xiaoxi Zeng3, Huile Gao4, Yong Yuan5.   

Abstract

Esophageal cancer (EC) is a common gastrointestinal malignancy with poor prognosis and high mortality. Although combined therapeutic strategies have been developed, the 5-year survival rate of patients with EC remains relatively poor. Conventional anti-cancer drug delivery techniques have some shortcomings, such as nontargeted delivery and nonspecific toxicity. Nanoparticles (NPs) provide a promising platform for delivering drugs in various therapeutic modalities for EC, which possess several remarkable advantages in cancer therapy, such as reduced side effects, prolonged circulation time, and preferential accumulation at the tumor site. In this review, we summarized various types of NPs applied in the treatment of EC, including polymers, micelles, liposomes, inorganic NPs and organic NPs. Meanwhile, we discussed the efficacy and safety of newly designed nanomedicine in various treatments of EC, including chemotherapy, radiotherapy, gene therapy, photodynamic therapy (PDT), photothermal therapy (PTT), and their synergetic therapy. In addition, nanomedicine applied in tumor imaging and diagnoses were also reviewed. Current studies have suggested the potential advantages of nanoformulations over conventional formulations. More researches to promote clinical translation of nanomedicine for EC are anticipated in the future.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug delivery; Esophageal cancer; Imaging; Nanomedicine; Nanoparticle

Year:  2022        PMID: 35074509     DOI: 10.1016/j.semcancer.2022.01.007

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   17.012


  7 in total

1.  Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Jiahan Cheng; Minzhang Guo; Yushang Yang; Yilin Liu; Weipeng Hu; Qixin Shang; Chuan Li; Liang Xia; Yun Wang; Wenping Wang; Dong Tian; Yong Yuan; Yang Hu; Longqi Chen
Journal:  Front Immunol       Date:  2022-03-11       Impact factor: 7.561

2.  Prognostic Value of Geriatric Nutritional Risk Index in Esophageal Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jianfeng Zhou; Pinhao Fang; Xiaokun Li; Siyuan Luan; Xin Xiao; Yinmin Gu; Qixin Shang; Hanlu Zhang; Yushang Yang; Xiaoxi Zeng; Yong Yuan
Journal:  Front Nutr       Date:  2022-03-25

3.  Stemness-related gene signature for predicting therapeutic response in patients with esophageal cancer.

Authors:  Shaojin Zhu; Gengxin Zhang; Qi You; Fei Li; Boying Ding; Feng Liu; Lan Jiang
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

4.  Intelligent Identification of Early Esophageal Cancer by Band-Selective Hyperspectral Imaging.

Authors:  Tsung-Jung Tsai; Arvind Mukundan; Yu-Sheng Chi; Yu-Ming Tsao; Yao-Kuang Wang; Tsung-Hsien Chen; I-Chen Wu; Chien-Wei Huang; Hsiang-Chen Wang
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

Review 5.  Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications.

Authors:  Pinhao Fang; Jianfeng Zhou; Zhiwen Liang; Yushang Yang; Siyuan Luan; Xin Xiao; Xiaokun Li; Hanlu Zhang; Qixin Shang; Xiaoxi Zeng; Yong Yuan
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

6.  Comparison of complications and long-term survival after minimally invasive esophagectomy versus open esophagectomy in patients with esophageal cancer and chronic obstructive pulmonary disease.

Authors:  Yu Rong; Yanbing Hao; Jun Xue; Xiaoyuan Li; Qian Li; Li Wang; Tian Li
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

7.  Prognostic value of micro-RNA 375, 133, 143, 145 in esophageal carcinoma: A systematic review and meta-analysis.

Authors:  Pinhao Fang; Jianfeng Zhou; Xiaokun Li; Siyuan Luan; Xin Xiao; Qixin Shang; Hanlu Zhang; Yushang Yang; Xiaoxi Zeng; Yong Yuan
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.